ClinicalTrials.gg
Not yet recruitingNCT07457190Updated Mar 10, 2026

Pharmacokinetic Study of Buagafuran Capsules in Participants With Hepatic Impairment and Normal Hepatic Function

A Phase 1 interventional study of Buagafuran in Generalized Anxiety Disorder, sponsored by Beijing Union Pharmaceutical Factory Ltd. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-10.

Sponsored by Beijing Union Pharmaceutical Factory Ltd · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was expected by Aug 2026, 3 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies in Generalized Anxiety Disorder with a site in China — 16 open to participants now, 16 under way, 3 of them phase 3. Generalized Anxiety Disorder · China.

Planned enrollment
20th of 20
24 · median 122
Started
2026
with 7 others
Phase 1
2 of 23
1 open now
Primary completion
2026-08
later than 6 of 15 live
Registered
19th of 23
by date
Lead sponsor
3 of 23
Beijing Union Pharmaceutical Factory Ltd

Among the 23 studies in Generalized Anxiety Disorder with a site in China, this one is the 20th largest by planned enrollment of the 20 interventional ones that give a count, is one of 8 that started in 2026, is one of 2 in phase 1, reaches primary completion later than 6 of the 15 other live ones, and was the 19th registered.

Generalized Anxiety Disorder

518 studies on the registry are indexed under Generalized Anxiety Disorder; 125 are open to participants now.

Browse Generalized Anxiety Disorder studies →

Open to participants now

16 of the 23 studies in Generalized Anxiety Disorder with a site in China are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 86 Generalized Anxiety Disorder studies recruiting now, 32 (37%) set no upper age limit and 52 (60%) stop at 75 or younger; 15 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Generalized Anxiety Disorder with a site in China, or all of them as a file.
02

Study summary

This study adopts a non-randomized, open label, parallel, single-dose design to evaluate the safety and pharmacokinetic characteristics of Buagafuran capsules in participants with hepatic impairment.

Read the detailed description

This study adopts a non-randomized, open label, parallel, single-dose design to evaluate the safety and pharmacokinetic characteristics of Buagafuran capsules in participants with hepatic impairment.

This study enrolled 24 participants, both male and female. Three experimental groups were set up, with Day1 taking 30 mg Buagafuran capsules on an empty stomach in the morning.Participants can leave on Day3.

03

Conditions studied

  • Generalized Anxiety Disorder
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntarily sign an form before the start of activities related to this trial, understand the procedures and methods of this trial, and be willing to strictly follow the clinical trial protocol to complete this trial;
  2. Participants (including partners) are willing to have no fertility plans from screening to within 6 months after the last administration of the study drug, and voluntarily adopt highly effective measures;
  3. On the day of signing the informed consent form, the age range is 18 to 70 years old (including both ends), and both males and females are eligible;
  4. Male participants should weigh no less than 50 kg, and female participants should weigh no less than 45 kg; (BMI) should be between 18 and 32 kg/m2 (including both ends), with BMI=weight (kg)/height (m2);
  5. rate ≥ 60 mL/min;
  6. Participants with normal hepatic function must also meet all of the following criteria: a): Weight matching with the hepatic impairment group, with an average weight range of ± 10 kg; b): Age matching with the hepatic impairment group, with an average age range of ± 10 years; c): The number of participants of each gender is similar to that of the hepatic impairment group (mean ± 1 participant/gender);
  7. Participants with hepatic impairment must also meet all of the following conditions: a): Chronic hepatic impairment caused by primary hepatic diseases, and hepatic impairment patients with classification of A or B; b):The clinical diagnosis is cirrhosis; c): Individuals who have a stable medication regimen for treating hepatic impairment, complications, and other accompanying diseases for at least 14 days prior to taking the drug, and whose medication does not require adjustment; or those who have not taken medication;

Exclusion criteria

Exclusion Criteria:

  1. Allergic constitution, including individuals with a history of severe drug allergies or drug reactions, known to be allergic to the study drug or any component of the study drug;
  2. During the screening period, the showed a of>470 milliseconds in males and>480 milliseconds in females;
  3. Individuals with a history of swallowing difficulties or any gastrointestinal diseases that affect drug absorption, including frequent nausea or vomiting caused by any underlying cause;
  4. Those who need treatment for bacterial, viral, parasitic or fungal infection with any clinical symptoms during screening (excluding and ), and those who have a history of serious active infection within 1 month before screening;
  5. Individuals who have undergone major surgeries within the previous 6 months (defined as surgeries involving intracranial, chest, abdominal, pelvic, or limb organs that cause significant tissue trauma and require long-term recovery (such as organ transplantation, heart surgery, or joint replacement), or those who plan to undergo surgery during the study period; Individuals with a history of liver transplantation; Participants who have undergone surgery that may affect drug absorption, distribution, metabolism, and excretion in the past (such as gastric and duodenal resection surgery) or who may be hospitalized due to surgery or other reasons during the expected trial period;
  6. Screening individuals who have received the vaccine within the previous 14 days or plan to receive the vaccine during the study period;
  7. Screening individuals who have donated blood or lost blood ≥ 200 mL within the first 3 months, or plan to donate blood during the trial period or within 1 month after the trial ends;
  8. Screening for individuals who have used other clinical trial drugs within the previous 3 months or plan to participate in other clinical trials during the study period;
  9. Within one month prior to screening (or 5 times the half-life, whichever is longer), strong or moderate inducers or inhibitors of CYP2B6, , renal transporter inhibitors, etc. have been used;
  10. Consuming grapefruit or products containing grapefruit, food or beverages containing caffeine, xanthine, or alcohol (including chocolate, tea, coffee, cola, etc) 48 hours prior to receiving the drug; Those who engage in vigorous exercise or have other factors that affect drug absorption, distribution, metabolism, excretion, etc;
  11. Screening for alcoholics within the first 3 months, those who consume more than 14 units of alcohol per week (1 unit=360 mL of beer, 45 mL of strong liquor with an alcohol content of 40%, or 150 mL of wine) or have a positive alcohol screening result; Individuals who smoke an average of 10 or more cigarettes per day within the first 3 months of screening;
  12. Individuals with a history of drug use, drug abuse, or positive drug abuse screening;
  13. Pregnant or lactating women, or women of childbearing age who test positive for pregnancy;
  14. Those who cannot tolerate venipuncture or have a history of needle and blood dizziness;
  15. Other reasons why researchers believe it is not suitable for inclusion;

    Participants with normal hepatic function who meet any of the following exclusion criteria need to be excluded:

  16. History of hepatic impairment;
  17. Individuals who have previously or currently suffered from any clinically serious diseases such as circulatory system, endocrine system, nervous system, digestive system, respiratory system, hematology, immunology, psychiatry, and metabolic abnormalities, or any other diseases that may interfere with the test results;
  18. Abnormal physical examination, vital signs, laboratory tests, 12 lead electrocardiogram, abdominal ultrasound and other examinations have clinical significance as determined by the researchers;
  19. Those who are positive in any index screening of hepatitis B surface antigen, hepatitis C antibody, antigen/antibody or syphilis antibody;
  20. Have used any prescription drugs, over-the-counter drugs, herbal medicines, or supplements within 14 days prior to receiving the investigational drug.

    Participants with hepatic impairment who meet any of the following exclusion criteria must be excluded:

  21. Participants have any of the following conditions: acute hepatic function damage caused by various reasons; History of liver transplantation; And researchers believe that patients with liver cirrhosis complicated with the following complications: including but not limited to hepatic failure, hepatic encephalopathy, hepatocellular carcinoma (excluding liver cancer patients who have received curative treatment and have not ; excluding liver cancer patients with BCLC stage 0), and those who have experienced esophageal and gastric variceal bleeding within the past 3 months before screening;
  22. The laboratory test results during screening meet any of the following criteria: (a) or AST>10 × ; (b) NE#\<0.75×109/L;(c) HGB\<60 g/L; (d) AFP>100 ng/mL; (e) count\<40 × 109/L; any remaining abnormalities that have clinical significance and have been determined by the researchers to be unsuitable for participation in this trial;
  23. Individuals who test positive for HIV antigen/antibody screening; If syphilis antibodies are positive, rapid plasma reagin (RPR) testing should be added. If RPR is also positive, it should be excluded;
  24. In addition to the primary liver disease itself, those who have previously or currently suffered from other serious organ systemic diseases, including but not limited to gastrointestinal, respiratory, renal, neurological, blood, endocrine, tumor, immune, psychiatric or cardiovascular diseases, or abnormalities with clinical significance such as physical examination and chest radiograph, and have been determined by the research doctor to be unsuitable for participation in this trial.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    Child-Pugh A

    participants with Mild Hepatic Impairment: All participants to receive study drug (Buagafuran 30mg) on Day 1

    Drug: Buagafuran

  • Experimental
    Child-Pugh B

    Participants with Moderate Hepatic Impairment: All participants to receive study drug (Buagafuran 30mg) on Day 1

    Drug: Buagafuran

  • Experimental
    Normal Hepatic Function

    participants with Normal Hepatic Function: All participants to receive study drug (Buagafuran 30mg) on Day 1

    Drug: Buagafuran

Interventions

  • DrugBuagafuran

    participants to receive Buagafuran capsules 30 mg on an empty stomach on the morning of Day1

    Also known as: AF-5

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics of Buagafuran(Cmax)

    Maximum observed plasma concentration

    Time frame: from Day1 to Day3

  2. Pharmacokinetics of Buagafuran(AUC0-t)

    Area under the plasma concentration-time curve from time 0 to time of the last measurable concentration

    Time frame: from Day1 to Day3

  3. Pharmacokinetics of Buagafuran(AUC0-inf)

    Area under the plasma concentration-time curve from time 0 to infinity

    Time frame: from Day1 to Day3

Secondary outcomes

  1. incidence of Adverse Events

    To evaluate the safety of a single dose of 30mg Buagafuran administered in participants with hepatic impairment

    Time frame: from Day1 to Day3

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Mar 2026; primary completion for Aug 2026, 5 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2026
First posted
Mar 9, 2026
StartEst.
Mar 2026
Primary completionEst.
Aug 2026
CompletionEst.
Dec 2026
Last update
Mar 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07457190
Lead sponsor
Beijing Union Pharmaceutical Factory Ltd
Responsible party
Sponsor
First posted
Mar 9, 2026
Start date
Mar 2026 (estimated)
Primary completion
Aug 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Mar 10, 2026

Study contacts

Feng You
Contact
18911123155@189.cn
86+18911123155
Hong Zhang
principal investigator · The First Hospital of Jilin University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion